Landfar Bio-medicine Co., Ltd (SHE:000504)
8.15
-0.12 (-1.45%)
Sep 2, 2026, 2:20 PM CST
Landfar Bio-medicine Revenue
Landfar Bio-medicine had revenue of 176.61M CNY in the quarter ending June 30, 2026, with 506.11% growth. This brings the company's revenue in the last twelve months to 660.26M, up 409.01% year-over-year. In the year 2025, Landfar Bio-medicine had annual revenue of 415.94M with 209.37% growth.
Revenue (ttm)
660.26M
Revenue Growth
+409.01%
P/S Ratio
4.13
Revenue / Employee
2.09M
Employees
316
Market Cap
2.73B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 415.94M | 281.49M | 209.37% |
| Dec 31, 2024 | 134.45M | -2.34M | -1.71% |
| Dec 31, 2023 | 136.79M | -63.55M | -31.72% |
| Dec 31, 2022 | 200.35M | 43.73M | 27.92% |
| Jan 1, 2022 | 156.62M | -18.95M | -10.79% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beijing Kawin Technology Share-Holding | 1.23B |
| Shanghai Universal Biotech | 1.15B |
| Shandong Sito Bio-technology | 1.12B |
| Zhejiang East Asia Pharmaceutical | 990.47M |
| Guangdong VTR Bio-Tech | 814.07M |
| Hubei Goto Biopharm Group | 650.05M |
| Zhejiang Shouxiangu Pharmaceutical | 611.43M |
| Shanghai Model Organisms Center | 432.55M |